Transparency and reporting characteristics of COVID-19 randomized controlled trials.

Kapp, Philipp; Esmail, Laura; Ghosn, Lina; Ravaud, Philippe; Boutron, Isabelle

Kapp, Philipp; Esmail, Laura; Ghosn, Lina; Ravaud, Philippe; Boutron, Isabelle.

Afiliación

Kapp P; Université Paris Cité, Inserm, INRAE, Centre of Research in Epidemiology and Statistics (CRESS), F-75004, Paris, France.
Esmail L; Centre d'Épidémiologie Clinique, AP-HP, Hôpital Hôtel-Dieu, F-75004, Paris, France.
Ghosn L; Cochrane France, F-75004, Paris, France.
Ravaud P; Institute for Evidence in Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, D-79110, Freiburg, Germany.
Boutron I; Université Paris Cité, Inserm, INRAE, Centre of Research in Epidemiology and Statistics (CRESS), F-75004, Paris, France.

BMC Med ; 20(1): 363, 2022 09 26.

Article en En | MEDLINE | ID: mdl-36154932

Asunto(s)

COVID-19; Humanos; Difusión de la Información; Revisión por Pares; Ensayos Clínicos Controlados Aleatorios como Asunto; Informe de Investigación

Palabras clave

CONSORT; COVID-19; Peer review; Completeness of reporting; Quality of reporting; Randomized controlled trial; Selection bias; Selective outcome reporting; Transparency

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: BMC Med Asunto de la revista: MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google